Acne vulgaris is a very common condition which can cause significant physical and psychological morbidity. This pathway relates to adolescents and adults > 12 years. About 15% of the adolescent population have sufficient problems to seek treatment. This is an age when self-esteem is very important.

Although in most patients acne clears up by the early 20s, more severe acne tends to last longer and a group of patients have persistent acne lasting up to the age of 30 - 40 years. Acne may scar – most of the time this is preventable by using the correct treatment given in a timely fashion. Given the large numbers of patients who suffer from acne, it is important that these should be managed effectively in the community in the majority of cases. Early effective treatment for all with the condition will prevent scarring and promote self-esteem. Hospital referral should be reserved for those patients requiring hospital only drugs to control their disease.

Referral criteria

Refer routinely to dermatology if:

- Severe acne or nodular cystic acne - refer early
- Moderate acne only partially responding to treatment and starting to scar
- Inadequate response to at least two systemic antibiotics PLUS topical treatments (use topical and oral treatment in combination), each given for a minimum of three months.
- Patients with associated and severe psychological symptoms, regardless of the physical signs
- If patient does not meet referral criteria, treat in primary care.

Self-care advice

Advise about washing and skin care. In general, it is recommended that people with acne:

- Do not wash more than twice a day.
- Use a mild soap or cleanser and lukewarm water (as very hot or cold water may worsen acne).
- Do not use vigorous scrubbing when washing acne-affected skin; the use of abrasive soaps, cleansing granules, astringents, or exfoliating agents should be discouraged (advise use of a soft wash-cloth and fingers instead).
- Should not attempt to 'clean' blackheads. Scrubbing or picking acne is liable to worsen the condition.
- Ideally, should avoid excessive use of makeup and cosmetics.
- Use a fragrance-free, water-based emollient if dry skin is a problem (several topical acne drugs dry the skin). The use of ointments or oil-rich creams should be avoided as these can clog pores.

Advise about non-prescription treatments.

- Benzoyl peroxide is a useful topical drug available over-the-counter. However, there is a lack of evidence of benefit for other over-the-counter drugs.
- Complementary and alternative medicines (for example herbal medicines) are not usually harmful but there is a general lack of evidence to support their use.
Types of Acne

Figure: 1
Mild acne
Comedones (blue arrow), pustules (black arrow) and excoriated lesions (green arrow)

Figure: 2
Acne with open comedones (blackheads)

Figure: 3
Mild papular/pustular acne

Figure: 4
Severe inflammatory acne; many pustules and actively inflamed nodules
Figure: 5
Severe acne with nodules

Copied with kind permission from Dermatoweb

Figure: 6
Ice-pick scars

http://www.pcds.org.uk/clinical-guidance/acne-vulgaris
## Treatment of Acne Vulgaris

<table>
<thead>
<tr>
<th></th>
<th>Comedonal acne</th>
<th>Mild papular / pustular acne</th>
<th>Moderate inflammatory acne</th>
<th>Moderate-severe acne in women</th>
</tr>
</thead>
</table>
| **1st line treatment choices (green traffic light categorised)** | • Adapalene (Differin ®)  
• Adapalene combined with benzoyl peroxide 2.5%(Epiduo ®)  
• Isotretinoin (eg Isotrex ®) | Use a combination product e.g.  
• Duac ® gel (benzoyl peroxide/clindamycin)  
• Treclin ® gel (tretinoin/clindamycin)  
• Epiduo ® gel (adapalene/benzoyl peroxide) | Combine systemic antibiotics with topical agents referred to in treatment of comedonal acne  
• Lymecycline 408 mg OD (Tetralysal ®)  
• Doxycycline 100 mg daily  
• Oxytetracycline 500 mg BD  
N.B do not use Treclin® with the above tetracyclines.  
Switch to an alternative oral antibiotic if no response in 16 weeks, can be of the same class | • If no contraindications consider adding in Dianette ® to topical / systemic treatments  
• Consider Dianette in patients with significant endocrinopathies such as PCOS |
| **2nd line treatment choices (where 1st line ineffective, contraindicated or not tolerated)** | • Azelaic acid | • Aknemycin ® Plus solution (erythromycin/tretinoin)  
• Isotrexin ® gel (erythromycin/isotretinoin) | • erythromycin 500 mg BD  
• clarithromycin 250 mg BD  
N.B if combining topical antibiotic with oral antibiotic can be of the same class | |
| **Notes** | **Follow-up**  
• It is important to have a way of monitoring response to treatment, e.g. using serial photography or standardised grading methods | **Duration of treatment**  
• Following sustained improvement to treatment (at least three months) consider discontinuing systemic treatment; continue topical treatments.  
• Treatment is likely to be required for several years, for much of this time this could be an appropriate topical treatment, adding systemic treatment | |
for flare-ups

**Poor responders to treatment**

- Wrong diagnosis e.g. rosacea
- Poor compliance - due to a long history of acne, side-effects of treatment such as photosensitivity caused by doxycycline or irritation to topical treatments. If local irritation / dermatitis develops consider stopping treatment for a few days; using an oil-free moisturiser once or twice a day; if necessary using 1% hydrocortisone cream for five days twice daily; then reintroducing the treatment gradually e.g. two to three nights a week
- *P. acnes* resistance is relevant for 10-20% of patients on tetracycline; 65% on erythromycin; more likely following many course of oral and/or topical antibiotics, and in those who were doing well and are now responding badly
- If *P. acnes* resistance suspected, prescribe Epiduo® gel or consider changing the type of systemic antibiotic

1. It is not advisable to prescribe oral and topical antibiotics of different chemical groups simultaneously.
2. Lymecycline 408 mg OD (Tetralysal®) an hour before food, or doxycycline 100 mg daily should be seen as first line as they are more effective. The latter can occasionally cause photosensitivity. Contraindicated in pregnancy and in patients aged under 12
3. Oxytetracycline 500 mg BD is cheaper. Contraindicated in pregnancy and in patients aged under 12. NB Minocycline is not recommended due to the increased risk of hepatotoxicity and lupus-like conditions.

**Prices and prescribing information**

<table>
<thead>
<tr>
<th>Product name</th>
<th>Dose</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adapalene 0.1% w/w (Differin Cream/Gel)</td>
<td>Apply to the acne affected areas once a day before retiring and after washing. A thin film of cream/gel should be applied, with the fingertips, avoiding the eyes and lips. Since it is customary to alternate therapies in the treatment of acne, assess the continued improvement after three months of treatment. Ensure that the affected areas are dry before application. With patients for whom it is necessary to reduce the frequency of application or to temporarily discontinue treatment, frequency of application may be restored or therapy resumed once it is judged that the patient can again tolerate the treatment.</td>
<td>Gel/cream 45 g = £16.43.</td>
</tr>
<tr>
<td>Adapalene 0.1%, benzoyl peroxide 2.5% (Epiduo® gel)</td>
<td>Apply to the entire acne affected areas once a day in the evening on a clean and dry skin. A thin film of gel should be applied, with the fingertips, avoiding the eyes and lips. If irritation occurs, apply non-comedogenic moisturizers, use less frequently (e.g. every other day), suspend use temporarily, or discontinue use altogether. The duration of treatment should be determined on the basis of the clinical condition. Early signs of clinical improvement usually appear after 1 to 4 weeks of treatment</td>
<td>45 g = £19.53.</td>
</tr>
<tr>
<td>Product Name</td>
<td>Description</td>
<td>Price</td>
</tr>
<tr>
<td>-------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Isotretinoin 0.05% w/w (Isotre ^® Gel )</td>
<td>Apply sparingly over the entire affected area once or twice daily, preferably after washing and drying the skin. If undue irritation (redness, peeling, or discomfort) occurs, reduce frequency of application or temporarily interrupt treatment. The normal frequency of application should be resumed once the irritation subsides. Treatment should be discontinued if the irritation persists. 6-8 weeks of treatment may be required before the therapeutic effect is observed.</td>
<td>£5.94</td>
</tr>
<tr>
<td>Duac® Once Daily Gel, benzoyl peroxide 3%, clindamycin 1%</td>
<td>Duac Once Daily Gel should be applied once daily in the evening, to the entire affected area. Excessive application will not improve efficacy, but may increase the risk of skin irritation. If excessive dryness or peeling occurs, frequency of application should be reduced or application temporarily interrupted. The safety and efficacy of Duac® Once Daily Gel has not been studied beyond 12 weeks in acne vulgaris clinical trials, so treatment should not exceed more than 12 weeks of continuous use.</td>
<td>£13.14, £26.28</td>
</tr>
<tr>
<td>Clindamycin 1% tretinoin 0.025% gel ( Treclin gel)</td>
<td>Apply once daily at bedtime after the the entire face is washed with mild soap and dried. A pea-sized amount of medication should be squeezed onto one fingertip, dot onto the chin, cheeks, nose, and forehead; then gently rub over the entire face. Treatment should not exceed 12 weeks of continuous use without careful evaluation. Improvement may not be observed for several weeks after starting treatment.</td>
<td>£11.94*</td>
</tr>
<tr>
<td>Azelaic acid 20% (Skinoren® 20% Cream)</td>
<td>Apply to the affected areas of skin twice daily (mornings and evenings), and rubbed in gently. 2.5 cm (approx. 0.5 g) of cream is sufficient for the entire facial area. If other areas of acne, in addition to the face require treatment, for example the chest and back, the amount of cream should be adjusted accordingly. Patients with sensitive skin should be advised to use Skinoren only once a day (in the evening) for the first week of treatment and then proceed to twice daily applications. Before application, the skin should be thoroughly cleaned with plain water and dried. A mild skin-cleansing agent may be used. The duration of use can vary from patient to patient and also depends on the severity of the acne. In general, a distinct improvement becomes apparent after about 4 weeks. To obtain the best results, Skinoren Cream should be used continuously over a period of several months</td>
<td>£3.74</td>
</tr>
<tr>
<td>Erythromycin Ph Eur 4% w/w and tretinoin BP 0.025% w/w (Aknemycin® Plus solution)</td>
<td>Apply to the affected areas once or twice daily. Treatment should continue for 9-12 weeks according to the condition of the skin. It should be noted that therapeutic improvement may not be observed for several weeks after starting treatment. Excess application of Aknemycin® Plus should be avoided since it may result in marked erythema, drying and discomfort of the treated areas</td>
<td>£7.05</td>
</tr>
<tr>
<td>Isotretinoin 0.05% w/w and erythromycin 2.00% w/w (Isotrexin ^® gel)</td>
<td>Apply in a thin film over the entire affected area once or twice daily after cleaning the skin gently with a mild cleanser and drying fully. Avoid close proximity to eyes, lips, and other mucous membranes. 6-8 weeks of treatment may be required before the full therapeutic effect is observed. Evaluate the benefit of continuing treatment beyond 12 weeks of uninterrupted use, taking account an increased</td>
<td>£7.47</td>
</tr>
</tbody>
</table>
risk of antimicrobial resistance

Avoid over-saturation with Isotrexin® to the extent that excess medication could run into their eyes, and angles of the nose or other areas where treatment is not intended. If applied excessively, marked redness, peeling or discomfort may occur. Should this occur accidentally or through over enthusiastic use patients may use a moisturiser as needed and should reduce frequency of application or application should be discontinued for a few days. The normal frequency of application should be resumed once the irritation subsides. Treatment should be discontinued if the irritation persists.

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage and Duration</th>
<th>Tolerance and Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymecycline</td>
<td>408mg (one capsule) daily: treatment should be continued for at least 8 weeks.</td>
<td>28-cap pack = £5.14</td>
</tr>
<tr>
<td>Doxyclline</td>
<td>100mg daily with food or fluid for 6 to 12 weeks. Swallow with plenty of fluid in either the resting or standing position and well before going to bed for the night to reduce the likelihood of oesophageal irritation and ulceration. If gastric irritation occurs, give with food or milk. Studies indicate that the absorption of doxycycline is not notably influenced by simultaneous ingestion of food or milk</td>
<td>50 mg, 28-cap pack = £1.29 100 mg, 8-cap pack = £0.87</td>
</tr>
<tr>
<td>Oxytetracycline</td>
<td>500mg twice daily in single or divided doses should be administered for at least 3 months. The tablets are for oral administration and are best taken on an empty stomach (1 hour before food or two hours after). If gastric irritation occurs, tablets should be taken with food. Tablets should be taken well before going to bed.</td>
<td>250mg; 28-tab pack = £1.07</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>500mg twice daily</td>
<td>250mg; 28-tab pack = £1.45</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>250mg twice daily. Swallow with a sufficient amount of fluid (e.g. one glass of water). Clarithromycin may be given irrespective of food intake</td>
<td>250 mg, 14-tab pack = £1.36</td>
</tr>
</tbody>
</table>

**Based on:**


References


Version 1

Reviewed by dermatology working group: September 2016

Approved by Dorset Medicines Advisory Group: January 2017

For review: January 2019 or following new information